MX2021004868A - Diacuerpos cd123 x cd3 biespecificos para el tratamiento de neoplasias hematologicas. - Google Patents
Diacuerpos cd123 x cd3 biespecificos para el tratamiento de neoplasias hematologicas.Info
- Publication number
- MX2021004868A MX2021004868A MX2021004868A MX2021004868A MX2021004868A MX 2021004868 A MX2021004868 A MX 2021004868A MX 2021004868 A MX2021004868 A MX 2021004868A MX 2021004868 A MX2021004868 A MX 2021004868A MX 2021004868 A MX2021004868 A MX 2021004868A
- Authority
- MX
- Mexico
- Prior art keywords
- expression
- patient
- genes
- malignancy
- hematologic malignancies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752659P | 2018-10-30 | 2018-10-30 | |
| US201862769078P | 2018-11-19 | 2018-11-19 | |
| US201962878368P | 2019-07-25 | 2019-07-25 | |
| PCT/US2019/058616 WO2020092404A1 (en) | 2018-10-30 | 2019-10-29 | Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004868A true MX2021004868A (es) | 2021-09-08 |
Family
ID=70464448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004868A MX2021004868A (es) | 2018-10-30 | 2019-10-29 | Diacuerpos cd123 x cd3 biespecificos para el tratamiento de neoplasias hematologicas. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210395374A1 (enExample) |
| EP (1) | EP3873606A4 (enExample) |
| JP (2) | JP7551066B2 (enExample) |
| KR (1) | KR102943465B1 (enExample) |
| CN (3) | CN113286633A (enExample) |
| AU (1) | AU2019371243A1 (enExample) |
| BR (1) | BR112021008283A2 (enExample) |
| CA (1) | CA3118081A1 (enExample) |
| IL (1) | IL282827A (enExample) |
| MX (1) | MX2021004868A (enExample) |
| SG (1) | SG11202104367RA (enExample) |
| WO (1) | WO2020092404A1 (enExample) |
| ZA (1) | ZA202102775B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022025834A2 (pt) * | 2020-06-18 | 2023-01-10 | Macrogenics Inc | Método para determinar se um paciente seria um respondedor adequado ao uso de uma molécula biespecífica cd123 x cd3 para tratar uma malignidade hematológica e método de tratamento de uma malignidade hematológica |
| AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| TW202241469A (zh) * | 2021-02-20 | 2022-11-01 | 美商凱特製藥公司 | 免疫療法 |
| WO2023092119A2 (en) * | 2021-11-22 | 2023-05-25 | Ludwig Institute For Cancer Research Ltd | Methods for predicting responsiveness to a cancer therapy |
| EP4499683A1 (en) * | 2022-03-29 | 2025-02-05 | NGM Biopharmaceuticals, Inc. | Ilt3 and cd3 binding agents and methods of use thereof |
| EP4507790A1 (en) | 2022-04-11 | 2025-02-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| CN120857940A (zh) | 2023-02-17 | 2025-10-28 | 瑞泽恩制药公司 | 对cd3/taa双特异性抗体有反应的诱导型nk细胞 |
| KR20250134857A (ko) * | 2024-03-05 | 2025-09-12 | 사회복지법인 삼성생명공익재단 | 비소세포폐암 환자의 면역 관문 억제제에 대한 반응성을 예측하는 방법, 장치, 및 컴퓨터프로그램 |
| CN120866362B (zh) * | 2025-07-15 | 2026-03-31 | 郑州大学第一附属医院 | 过表达ifitm2基因的car-t细胞、构建方法及其在免疫细胞疗法中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005201935B2 (en) * | 2004-05-06 | 2012-04-26 | Veridex, Llc | Prognostic for hematological malignancy |
| US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| US20160272720A1 (en) * | 2013-11-06 | 2016-09-22 | Memorial Sloan-Kettering Cancer Center | Compositions and Methods for the Treatment of Acute Myeloid Leukemias and Myelodysplastic Syndromes |
| PL3119807T3 (pl) * | 2014-03-19 | 2019-09-30 | Cellectis | Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów |
| JP2018538247A (ja) | 2015-10-23 | 2018-12-27 | 第一三共株式会社 | Ａｍｌを処置することに用いるための医薬組成物およびそれを必要とする対象においてａｍｌを処置する方法 |
| MX2018014950A (es) * | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| TWI790206B (zh) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| WO2019050521A1 (en) * | 2017-09-07 | 2019-03-14 | Macrogenics, Inc. | DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES |
-
2019
- 2019-10-29 AU AU2019371243A patent/AU2019371243A1/en active Pending
- 2019-10-29 US US17/290,061 patent/US20210395374A1/en active Pending
- 2019-10-29 KR KR1020217014961A patent/KR102943465B1/ko active Active
- 2019-10-29 EP EP19878838.2A patent/EP3873606A4/en active Pending
- 2019-10-29 CN CN201980087139.5A patent/CN113286633A/zh active Pending
- 2019-10-29 MX MX2021004868A patent/MX2021004868A/es unknown
- 2019-10-29 SG SG11202104367RA patent/SG11202104367RA/en unknown
- 2019-10-29 BR BR112021008283-2A patent/BR112021008283A2/pt unknown
- 2019-10-29 CN CN202411135769.4A patent/CN119236065A/zh active Pending
- 2019-10-29 CA CA3118081A patent/CA3118081A1/en active Pending
- 2019-10-29 WO PCT/US2019/058616 patent/WO2020092404A1/en not_active Ceased
- 2019-10-29 CN CN202411135807.6A patent/CN119280393A/zh active Pending
- 2019-10-29 JP JP2021548536A patent/JP7551066B2/ja active Active
-
2021
- 2021-04-26 ZA ZA2021/02775A patent/ZA202102775B/en unknown
- 2021-04-29 IL IL282827A patent/IL282827A/en unknown
-
2024
- 2024-08-21 JP JP2024139452A patent/JP2024178163A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113286633A (zh) | 2021-08-20 |
| JP2024178163A (ja) | 2024-12-24 |
| JP7551066B2 (ja) | 2024-09-17 |
| CN119236065A (zh) | 2025-01-03 |
| KR20210110567A (ko) | 2021-09-08 |
| WO2020092404A1 (en) | 2020-05-07 |
| SG11202104367RA (en) | 2021-05-28 |
| BR112021008283A2 (pt) | 2021-09-14 |
| KR102943465B1 (ko) | 2026-03-25 |
| IL282827A (en) | 2021-06-30 |
| US20210395374A1 (en) | 2021-12-23 |
| EP3873606A4 (en) | 2022-10-26 |
| JP2022513402A (ja) | 2022-02-07 |
| EP3873606A1 (en) | 2021-09-08 |
| ZA202102775B (en) | 2022-03-30 |
| WO2020092404A8 (en) | 2021-05-20 |
| CA3118081A1 (en) | 2020-05-07 |
| CN119280393A (zh) | 2025-01-10 |
| AU2019371243A1 (en) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004868A (es) | Diacuerpos cd123 x cd3 biespecificos para el tratamiento de neoplasias hematologicas. | |
| Vernot | Senescence-associated pro-inflammatory cytokines and tumor cell plasticity | |
| Goossens et al. | EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET | |
| Ajani et al. | Cancer stem cells: the promise and the potential | |
| Pinto et al. | Breast cancer stem cells and epithelial mesenchymal plasticity–implications for chemoresistance | |
| Wang et al. | The T box transcription factor TBX2 promotes epithelial-mesenchymal transition and invasion of normal and malignant breast epithelial cells | |
| Ye et al. | Distinct EMT programs control normal mammary stem cells and tumour-initiating cells | |
| Cheng et al. | Elevated invasive potential of glioblastoma stem cells | |
| Furlow et al. | Mechanosensitive pannexin-1 channels mediate microvascular metastatic cell survival | |
| Sayan et al. | Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL | |
| Driemel et al. | Context-dependent adaption of EpCAM expression in early systemic esophageal cancer | |
| BR112022012885A2 (pt) | Método para tratar um câncer que expressa cd70 em um sujeito, composição farmacêutica para o tratamento de um câncer que expressa cd70, e, kit | |
| Bergenfelz et al. | S100A9 expressed in ER− PgR− breast cancers induces inflammatory cytokines and is associated with an impaired overall survival | |
| Gao et al. | Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway | |
| Song et al. | Inhibitory effect of ginsenoside Rg3 on cancer stemness and mesenchymal transition in breast cancer via regulation of myeloid-derived suppressor cells | |
| ES2571235T3 (es) | Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3 | |
| Bibby et al. | MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma | |
| Kalra et al. | CARF enrichment promotes epithelial–mesenchymal transition via Wnt/β-catenin signaling: Its clinical relevance and potential as a therapeutic target | |
| Ding et al. | miR-200b restoration and DNA methyltransferase inhibitor block lung metastasis of mesenchymal-phenotype hepatocellular carcinoma | |
| MX2018006531A (es) | Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada. | |
| Sattler et al. | Sympathetic nerve signaling rewires the tumor microenvironment: a shift in “microenvironmental-ity” | |
| Msaki et al. | A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model | |
| El‐Gowily et al. | Differential mechanisms of autophagy in cancer stem cells: Emphasizing gastrointestinal cancers | |
| Yang et al. | BOP1 silencing suppresses gastric cancer proliferation through p53 modulation | |
| Won et al. | Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer |